Home > Publications Database > Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease. > print

001     155708
005     20240210114911.0
024 7 _ |a 10.1016/j.neurobiolaging.2020.07.002
|2 doi
024 7 _ |a pmid:32873436
|2 pmid
024 7 _ |a pmc:PMC7762821
|2 pmc
024 7 _ |a 0197-4580
|2 ISSN
024 7 _ |a 1558-1497
|2 ISSN
024 7 _ |a altmetric:89331497
|2 altmetric
037 _ _ |a DZNE-2021-00876
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Brown, Emmeline E
|b 0
245 _ _ |a Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease.
260 _ _ |a Amsterdam [u.a.]
|c 2021
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1707491033_2405
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The LRRK2 gene has rare (p.G2019S) and common risk variants for Parkinson's disease (PD). DNM3 has previously been reported as a genetic modifier of the age at onset in PD patients carrying the LRRK2 p.G2019S mutation. We analyzed this effect in a new cohort of LRRK2 p.G2019S heterozygotes (n = 724) and meta-analyzed our data with previously published data (n = 754). VAMP4 is in close proximity to DNM3, and was associated with PD in a recent study, so it is possible that variants in this gene may be important. We also analyzed the effect of VAMP4 rs11578699 on LRRK2 penetrance. Our analysis of DNM3 in previously unpublished data does not show an effect on age at onset in LRRK2 p.G2019S carriers; however, the inter-study heterogeneity may indicate ethnic or population-specific effects of DNM3. There was no evidence for linkage disequilibrium between DNM3 and VAMP4. Analysis of sporadic patients stratified by the risk variant LRRK2 rs10878226 indicates a possible interaction between common variation in LRRK2 and VAMP4 in disease risk.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Genetic modifiers
|2 Other
650 _ 7 |a Leucine-rich repeat kinase 2
|2 Other
650 _ 7 |a Parkinsonism
|2 Other
650 _ 7 |a Parkinson’s disease
|2 Other
650 _ 7 |a R-SNARE Proteins
|2 NLM Chemicals
650 _ 7 |a VAMP4 protein, human
|2 NLM Chemicals
650 _ 7 |a LRRK2 protein, human
|0 EC 2.7.11.1
|2 NLM Chemicals
650 _ 7 |a Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
|0 EC 2.7.11.1
|2 NLM Chemicals
650 _ 7 |a Dynamin III
|0 EC 3.6.5.5
|2 NLM Chemicals
650 _ 2 |a Age of Onset
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Dynamin III: genetics
|2 MeSH
650 _ 2 |a Epistasis, Genetic: genetics
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Genetic Association Studies
|2 MeSH
650 _ 2 |a Genetic Predisposition to Disease: genetics
|2 MeSH
650 _ 2 |a Genetic Variation: genetics
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Leucine-Rich Repeat Serine-Threonine Protein Kinase-2: genetics
|2 MeSH
650 _ 2 |a Linkage Disequilibrium: genetics
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Parkinson Disease: epidemiology
|2 MeSH
650 _ 2 |a Parkinson Disease: ethnology
|2 MeSH
650 _ 2 |a Parkinson Disease: genetics
|2 MeSH
650 _ 2 |a R-SNARE Proteins: genetics
|2 MeSH
650 _ 2 |a Risk
|2 MeSH
700 1 _ |a Blauwendraat, Cornelis
|0 P:(DE-2719)2810837
|b 1
|u dzne
700 1 _ |a Trinh, Joanne
|b 2
700 1 _ |a Rizig, Mie
|b 3
700 1 _ |a Nalls, Mike A
|b 4
700 1 _ |a Leveille, Etienne
|b 5
700 1 _ |a Ruskey, Jennifer A
|b 6
700 1 _ |a Jonvik, Hallgeir
|b 7
700 1 _ |a Tan, Manuela M X
|b 8
700 1 _ |a Bandres-Ciga, Sara
|b 9
700 1 _ |a Hassin-Baer, Sharon
|b 10
700 1 _ |a Brockmann, Kathrin
|0 P:(DE-2719)2811916
|b 11
|u dzne
700 1 _ |a Infante, Jon
|b 12
700 1 _ |a Tolosa, Eduardo
|b 13
700 1 _ |a Ezquerra, Mario
|b 14
700 1 _ |a Ben Romdhan, Sawssan
|b 15
700 1 _ |a Benmahdjoub, Mustapha
|b 16
700 1 _ |a Arezki, Mohamed
|b 17
700 1 _ |a Mhiri, Chokri
|b 18
700 1 _ |a Hardy, John
|b 19
700 1 _ |a Singleton, Andrew B
|b 20
700 1 _ |a Alcalay, Roy N
|b 21
700 1 _ |a Gasser, Thomas
|0 P:(DE-2719)2320009
|b 22
|u dzne
700 1 _ |a Grosset, Donald G
|b 23
700 1 _ |a Williams, Nigel M
|b 24
700 1 _ |a Pittman, Alan
|b 25
700 1 _ |a Gan-Or, Ziv
|b 26
700 1 _ |a Fernández-Santiago, Rubén
|0 P:(DE-2719)9000431
|b 27
|u dzne
700 1 _ |a Brice, Alexis
|b 28
700 1 _ |a Lesage, Suzanne
|b 29
700 1 _ |a Farrer, Matthew
|b 30
700 1 _ |a Wood, Nicholas
|b 31
700 1 _ |a Morris, Huw R
|b 32
700 1 _ |a Consortium, International Parkinson Disease Genomics
|0 P:(DE-HGF)0
|b 33
|e Collaboration Author
773 _ _ |a 10.1016/j.neurobiolaging.2020.07.002
|g Vol. 97, p. 148.e17 - 148.e24
|0 PERI:(DE-600)1498414-3
|p 148.e17 - 148.e24
|t Neurobiology of aging
|v 97
|y 2021
|x 0197-4580
856 4 _ |u https://www.sciencedirect.com/science/article/pii/S0197458020302189?via%3Dihub
856 4 _ |u https://pub.dzne.de/record/155708/files/DZNE-2021-00876.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/155708/files/DZNE-2021-00876.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:155708
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 1
|6 P:(DE-2719)2810837
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 11
|6 P:(DE-2719)2811916
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 22
|6 P:(DE-2719)2320009
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 27
|6 P:(DE-2719)9000431
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-345
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Population Studies and Genetics
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-10
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROBIOL AGING : 2021
|d 2022-11-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-10
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-10
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROBIOL AGING : 2021
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-10
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-10
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1210000
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21